Syndax Pharmaceuticals, Inc. Common Stock SNDX
i
Market dataready · fetched 2026-11-08T09:16:54.126Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T22:43:00.507179302Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-08T09:16:53.673942+00:00
Syndax Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 8.39 | 103.3% | 16.0% | |||
| 25Δ | 8.66 | 105.2% | 14.0% | |||
| 30Δ | 8.93 | 107.1% | 12.1% | |||
| 35Δ | 10.45 | 78.4% | 10.8% | 9.17 | 105.4% | 10.6% |
| 40Δ | 10.17 | 71.5% | 8.2% | 9.39 | 102.4% | 9.2% |
| 45Δ | 9.92 | 70.6% | 6.5% | 9.62 | 99.4% | 7.8% |
| 50Δ | 9.73 | 78.4% | 6.1% | 9.85 | 96.5% | 6.4% |
| 55Δ | 9.53 | 86.2% | 5.7% | 10.08 | 94.4% | 5.2% |
| 60Δ | 9.34 | 94.0% | 5.3% | 10.32 | 94.3% | 4.4% |
| 65Δ | 9.14 | 101.8% | 4.9% | 10.56 | 94.3% | 3.7% |
| 70Δ | 8.90 | 109.0% | 4.4% | 10.81 | 94.2% | 2.9% |
| 75Δ | 8.57 | 114.9% | 3.6% | 11.23 | 100.2% | 2.3% |
| 80Δ | 8.23 | 120.7% | 2.9% | 12.41 | 131.3% | 2.1% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.39
- IV
- 103.3%
- B/E move
- 16.0%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.66
- IV
- 105.2%
- B/E move
- 14.0%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.93
- IV
- 107.1%
- B/E move
- 12.1%
35Δ
- Pseudo strike
- 10.45
- IV
- 78.4%
- B/E move
- 10.8%
- Pseudo strike
- 9.17
- IV
- 105.4%
- B/E move
- 10.6%
40Δ
- Pseudo strike
- 10.17
- IV
- 71.5%
- B/E move
- 8.2%
- Pseudo strike
- 9.39
- IV
- 102.4%
- B/E move
- 9.2%
45Δ
- Pseudo strike
- 9.92
- IV
- 70.6%
- B/E move
- 6.5%
- Pseudo strike
- 9.62
- IV
- 99.4%
- B/E move
- 7.8%
50Δ
- Pseudo strike
- 9.73
- IV
- 78.4%
- B/E move
- 6.1%
- Pseudo strike
- 9.85
- IV
- 96.5%
- B/E move
- 6.4%
55Δ
- Pseudo strike
- 9.53
- IV
- 86.2%
- B/E move
- 5.7%
- Pseudo strike
- 10.08
- IV
- 94.4%
- B/E move
- 5.2%
60Δ
- Pseudo strike
- 9.34
- IV
- 94.0%
- B/E move
- 5.3%
- Pseudo strike
- 10.32
- IV
- 94.3%
- B/E move
- 4.4%
65Δ
- Pseudo strike
- 9.14
- IV
- 101.8%
- B/E move
- 4.9%
- Pseudo strike
- 10.56
- IV
- 94.3%
- B/E move
- 3.7%
70Δ
- Pseudo strike
- 8.90
- IV
- 109.0%
- B/E move
- 4.4%
- Pseudo strike
- 10.81
- IV
- 94.2%
- B/E move
- 2.9%
75Δ
- Pseudo strike
- 8.57
- IV
- 114.9%
- B/E move
- 3.6%
- Pseudo strike
- 11.23
- IV
- 100.2%
- B/E move
- 2.3%
80Δ
- Pseudo strike
- 8.23
- IV
- 120.7%
- B/E move
- 2.9%
- Pseudo strike
- 12.41
- IV
- 131.3%
- B/E move
- 2.1%
Options history
Table
| Date | IV (%) |
|---|---|
| 88.66% | |
| 75.74% | |
| 85.40% | |
| 75.47% | |
| 74.86% | |
| 83.90% | |
| 76.58% | |
| 64.83% | |
| 66.60% | |
| 71.71% |
Biotechnology
SPRO
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multidrug resistant (MDR)…
More →SPRY
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine aerosol with absorption technology for patients and their families at risk of severe allergic reactions to…
More →SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy, and other genetic…
More →SRRK
Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious diseases in which…
More →SRZN
Description unavailable
More →STOK
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops new antisense oligonucleotide (ASO) drugs to treat the underlying causes of serious genetic diseases…
More →